Other grades of this product :
| PF-5006739 Basic information |
| Product Name: | PF-5006739 | | Synonyms: | PF-5006739;4-[5-(4-fluorophenyl)-3-[1-(1,2-oxazol-3-ylmethyl)piperidin-4-yl]imidazol-4-yl]pyrimidin-2-amine;4-[4-(4-Fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-2-pyrimidinamine;PF 5006739;PF5006739;2-Pyrimidinamine, 4-[4-(4-fluorophenyl)-1-[1-(3-isoxazolylmethyl)-4-piperidinyl]-1H-imidazol-5-yl]-;PF-5006739 >=98% (HPLC) | | CAS: | 1293395-67-1 | | MF: | C22H22FN7O | | MW: | 419.45 | | EINECS: | | Product Categories: | | Mol File: | 1293395-67-1.mol |
| PF-5006739 Chemical Properties |
| storage temp. | room temp | | form | powder | | color | white to beige |
| RIDADR | UN 2811 6.1 / PGIII |
| PF-5006739 Usage And Synthesis |
| Biochem/physiol Actions | PF-5006739 is a potent inhibitor of casein kinases 1 delta (CK1δ) and 1 epsilon (CK1ε), key regulators of the suprachiasmatic nucleus (SCN) central clock and also linked to the development of drug addiction through PERIOD proteins (PER1–3) and dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32) modulation. PF-5006739 has low nM in vitro potency for CK1δ/ε (IC50 values of 3.9 nM for CK1δ and 17.0 nM for CK1ε) and high kinome selectivity. PF-5006739 induced profound phase delays in circadian periodicity in both nocturnal and diurnal animal models and attenuated opioid drug-seeking behavior in a rodent operant reinstatement model. |
| PF-5006739 Preparation Products And Raw materials |
|
日本语
한국어
Français
Deutsch
España
Türkiye